Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 AlteredExpression disease BEFREE KIT protein was expressed in 88% of the thymic carcinomas and 0% of the thymomas. 18448188 2008
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 CausalMutation disease CLINVAR Mutational status of EGFR and KIT in thymoma and thymic carcinoma. 18448188 2008
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 AlteredExpression disease LHGDN Absence of gene mutations in KIT-positive thymic epithelial tumors. 18486988 2008
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 CausalMutation disease CLINVAR Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. 17699867 2007
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 CausalMutation disease CLINVAR L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. 17372901 2007
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 AlteredExpression disease BEFREE In summary, COX-2 is expressed in all subtypes of thymomas and thymic carcinomas and thus represents, in addition to EGFR and KIT, a potential therapeutic target. 16823844 2006
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 CausalMutation disease CLINVAR Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. 15930355 2005
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 CausalMutation disease CLINVAR Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. 15201427 2004
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 CausalMutation disease CLINVAR Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. 12960119 2003
Entrez Id: 3265
Gene Symbol: HRAS
HRAS
0.140 GeneticVariation disease BEFREE Three type A thymomas harbored a nonsynonymous HRAS mutation. 27844328 2017
Entrez Id: 3265
Gene Symbol: HRAS
HRAS
0.140 GeneticVariation disease CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968 2014
Entrez Id: 3265
Gene Symbol: HRAS
HRAS
0.140 GeneticVariation disease BEFREE Genetic evaluation revealed a heterozygote mutation in the HRAS gene in both the keratinocytic epidermal nevus and thymoma but not in DNA extracted from blood lymphocytes, thus establishing the mutation as postzygotic. 24243633 2014
Entrez Id: 3265
Gene Symbol: HRAS
HRAS
0.140 AlteredExpression disease BEFREE We analyzed mutations in FGFR3, phosphoinositide 3 kinase catalytic alpha polypeptide (PIK3CA), v-akt murine thymoma viral oncogene homolog 1 (AKT1), v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS), and v-raf murine sarcoma viral oncogene homolog B1 (BRAF) in 88 urothelial cell carcinomas and the immunohistochemical expression of phospho-v-akt murine thymoma viral oncogene homolog (AKT) and mitogen-activated protein kinase 1 and 2 (pERK1/2) in 80 and 77 urothelial cell carcinomas, respectively. 22417847 2012
Entrez Id: 3265
Gene Symbol: HRAS
HRAS
0.140 GeneticVariation disease CLINVAR Thymic tumors: relevant molecular data in the clinic. 20859122 2010
Entrez Id: 3265
Gene Symbol: HRAS
HRAS
0.140 GeneticVariation disease BEFREE One thymoma and one thymic carcinoma harbored KRAS mutations (G12A and G12V, respectively), and one thymoma had a G13V HRAS mutation. 19861435 2009
Entrez Id: 207
Gene Symbol: AKT1
AKT1
0.100 Biomarker disease BEFREE The present study investigated, for the first time in the rabbit model, the effect of adding α-tocopherol (0, 100, 200 and 400µM) during IVM on putative transcripts involved in antioxidant defence (superoxide dismutase 2, mitochondrial (SOD2), glutathione peroxidase 1 (GPX1), catalase (CAT)), cell cycle regulation and apoptosis cascade (apoptosis tumour protein 53 (TP53), caspase 3, apoptosis-related cysteine protease (CASP3)), cell cycle progression (cellular cycle V-Akt murine thymoma viral oncogene homologue 1 (AKT1)), cumulus expansion (gap junction protein, alpha 1, 43 kDa (GJA1) and prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclo-oxygenase) (PTGS2)) and metabolism (glucose-6-phosphate dehydrogenase (G6PD)). 29966585 2018
Entrez Id: 5291
Gene Symbol: PIK3CB
PIK3CB
0.100 Biomarker disease BEFREE Genome-wide expression profiling of in vitro Mφ- and CD40L-stimulated CLL cells indicated activation of the phosphoinositide 3-kinase (PI3K)-V-Akt murine thymoma viral oncogene homolog (AKT)-mammalian target of rapamycin (mTOR) pathway, which was confirmed in ex vivo CLL LN material. 28192408 2017
Entrez Id: 5291
Gene Symbol: PIK3CB
PIK3CB
0.100 Biomarker disease BEFREE Bioinformatics analysis predicted the PI3K-v-akt murine thymoma viral oncogene homolog 1 (AKT) signaling pathway was dysregulated in P0-HUVECs from the PE group, which was associated with the miR-29a/c-3p downregulation. 28911139 2017
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE Genome-wide expression profiling of in vitro Mφ- and CD40L-stimulated CLL cells indicated activation of the phosphoinositide 3-kinase (PI3K)-V-Akt murine thymoma viral oncogene homolog (AKT)-mammalian target of rapamycin (mTOR) pathway, which was confirmed in ex vivo CLL LN material. 28192408 2017
Entrez Id: 5294
Gene Symbol: PIK3CG
PIK3CG
0.100 Biomarker disease BEFREE Bioinformatics analysis predicted the PI3K-v-akt murine thymoma viral oncogene homolog 1 (AKT) signaling pathway was dysregulated in P0-HUVECs from the PE group, which was associated with the miR-29a/c-3p downregulation. 28911139 2017
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE Bioinformatics analysis predicted the PI3K-v-akt murine thymoma viral oncogene homolog 1 (AKT) signaling pathway was dysregulated in P0-HUVECs from the PE group, which was associated with the miR-29a/c-3p downregulation. 28911139 2017
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Genome-wide expression profiling of in vitro Mφ- and CD40L-stimulated CLL cells indicated activation of the phosphoinositide 3-kinase (PI3K)-V-Akt murine thymoma viral oncogene homolog (AKT)-mammalian target of rapamycin (mTOR) pathway, which was confirmed in ex vivo CLL LN material. 28192408 2017
Entrez Id: 5294
Gene Symbol: PIK3CG
PIK3CG
0.100 Biomarker disease BEFREE Genome-wide expression profiling of in vitro Mφ- and CD40L-stimulated CLL cells indicated activation of the phosphoinositide 3-kinase (PI3K)-V-Akt murine thymoma viral oncogene homolog (AKT)-mammalian target of rapamycin (mTOR) pathway, which was confirmed in ex vivo CLL LN material. 28192408 2017
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Bioinformatics analysis predicted the PI3K-v-akt murine thymoma viral oncogene homolog 1 (AKT) signaling pathway was dysregulated in P0-HUVECs from the PE group, which was associated with the miR-29a/c-3p downregulation. 28911139 2017
Entrez Id: 207
Gene Symbol: AKT1
AKT1
0.100 Biomarker disease BEFREE These insulin enhancement effects were associated with increased expression of peroxisome proliferator-activated receptor α and γ (PPARα/γ) in fat, activation of Akt (v-Akt murine thymoma viral oncogene)/PKB (protein kinase-B) in fat and liver, and inactivation of c-Jun NH<sub>2</sub>-terminal protein kinases (JNK) in liver. 28709620 2017